Carbidopa suppresses prostate cancer via aryl hydrocarbon receptor-mediated ubiquitination and degradation of androgen receptor

Carbidopa, a peripheral decarboxylase inhibitor used with L-DOPA to treat Parkinson’s disease, has attracted significant interest in recent years for its anticancer effect. Increasing evidence reveals that Carbidopa can inhibit cancer cell growth and induce apoptosis through aryl hydrocarbon recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhiwei, Cai, Aimin, Zheng, Hailun, Huang, Huirong, Sun, Rui, Cui, Xiao, Ye, Weijian, Yao, Qing, Chen, Ruijie, Kou, Longfa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220950/
https://www.ncbi.nlm.nih.gov/pubmed/32404918
http://dx.doi.org/10.1038/s41389-020-0236-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220950/
https://www.ncbi.nlm.nih.gov/pubmed/32404918
http://dx.doi.org/10.1038/s41389-020-0236-x

Ejemplares similares